Log in to save to my catalogue

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_516836

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

About this item

Full title

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Publisher

London: Nature Publishing Group UK

Journal title

Nature reviews. Neurology, 2015-01, Vol.11 (1), p.41-55

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Key Points
Cerebrospinal fluid (CSF) biomarkers can track relevant pathophysiological changes that occur in the brains of patients with Alzheimer disease (AD)
In AD clinical trials, amyloid-β
1–42
(Aβ
1–42
), total tau (t-tau) and phosphorylated tau (p-tau) are used to measure target engagement, for enrichment or stratification of...

Alternative Titles

Full title

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_516836

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_516836

Other Identifiers

ISSN

1759-4758,1759-4766

E-ISSN

1759-4766

DOI

10.1038/nrneurol.2014.232